Yuk Ting Ma

Dr Yuk Ting Ma MBChB (hons), MRCP, PhD

Department of Immunology and Immunotherapy
Senior Clinical Lecturer in Hepatobiliary Oncology

Contact details

Telephone: +44 (0)121 371 3571
Fax: +44 121 371 3590
Email: y.t.ma@bham.ac.uk

Address: Department of Immunology and Immunotherapy
College of Medicine and Health
黑料吃瓜网
Edgbaston
Birmingham
B15 2TT
UK

Yuk Ting Ma is a Senior Clinical Lecturer in Hepatobiliary Oncology in the Department of Immunology and Immunotherapy and an Honorary Consultant in Hepatobiliary Oncology at the University Hospitals Birmingham NHS Foundation Trust.

Her research is focussed on understanding how epigenetic therapies may be used to reverse resistance to chemotherapy and also in understanding the immune responses following treatment in hepatobiliary cancers.

Qualifications

PhD, 黑料吃瓜网 - 2011
MRCP (UK) - 2003
MBChB (hons), 黑料吃瓜网 - 2000

Biography

Yuk Ting studied Medicine at the 黑料吃瓜网, graduating with honours in 2000. She undertook general medical training in Birmingham gaining Membership of the Royal Colleges of Physicians in 2003. She then undertook specialist training in Medical Oncology in the West Midlands region and was awarded a CRUK Clinical Research Training Fellowship in 2005.

Her PhD investigating smoking- and viral-induced epigenetic changes in cervical epithelia was supervised by Professor Paul Murray and the late Professor Ciaran Woodman, in the 黑料吃瓜网. In 2012, Yuk Ting was appointed as a Senior Clinical Lecturer in Hepatobliary Oncology at the 黑料吃瓜网, and as an Honorary Consultant in Hepatobiliary Oncology at the University Hospitals Birmingham NHS Foundation Trust.

Teaching

MSc in Clinical Oncology
- Clinical Lead
- Cancer Therapy and Management Module
BSc Biomedical Sciences
- Cancer and Stratified Medicine Module
- Cancer Pathogenesis and Treatment Module
- New Targets and Drugs in Cancer Therapy Module
MBChB - undergraduate teaching

Postgraduate supervision

Yuk Ting has supervised the laboratory projects of a number of BMedSci students

If you are interesting in studying any of these subject areas please contact Dr Yuk Ting Ma directly, or for any general doctoral research enquiries, please email mds-gradschool@contacts.bham.ac.uk.

For a full list of available Doctoral Research opportunities, please visit our Doctoral Research programme listings.

Research

The development of resistance to cytotoxic or targeted therapy in a cancer patient greatly limits the effectiveness of available anticancer therapies. A variety of mechanisms of resistance have been identified including enhanced drug metabolism, drug efflux from cancer cells and activation of alternative survival pathways. Recently dynamic chromatin modifications have been identified as a key determinant in the maintenance of subpopulations of cancer cells with high-level resistance to cytotoxic therapy. Dr Ma’s research focuses on understanding how epigenetic drugs may be used to reverse chemotherapy resistance.

Recent experimental studies have also shown that epigenetic drugs can have potent immunomodulating effects and Yuk Ting is also studying the immune responses in patients following treatment, and ultimately whether this may be modulated with epigenetic drugs.

Other activities

Member of the NCRI Upper GI CSG

Publications

Recent publications

Article

Rannikko, JH, Verlingue, L, De miguel, M, Pasanen, A, Robbrecht, D, Skytta, T, Iivanainen, S, Shetty, S, Ma, YT, Graham, DM, Arora, SP, Jaakkola, P, Yap, C, Xiang, Y, Mandelin, J, Karvonen, MK, Jalkanen, J, Karaman, S, Koivunen, JP, Minchom, A, Hollm茅n, M & Bono, P 2023, '', Cell Reports Medicine, vol. 4, no. 12, 101307.

Ghaneh, P, Palmer, D, Cicconi, S, Jackson, R, Halloran, CM, Rawcliffe, C, Sripadam, R, Mukherjee, S, Soonawalla, Z, Wadsley, J, Al-Mukhtar, A, Dickson, E, Graham, J, Jiao, L, Wasan, HS, Tait, IS, Prachalias, A, Ross, P, Valle, JW, O'Reilly, DA, Al-Sarireh, B, Gwynne, S, Ahmed, I, Connolly, K, Yim, K-L, Cunningham, D, Armstrong, T, Archer, C, Roberts, K, Ma, YT, Springfeld, C, Tjaden, C, Hackert, T, B眉chler, MW & Neoptolemos, JP 2023, '', The Lancet Gastroenterology & Hepatology, vol. 8, no. 2, pp. 157-168.

Mosconi, C, O鈥橰ourke, J, Kloeckner, R, Sturm, L, Golfieri, R, Celsa, C, Fateen, W, Odisio, BC, Garanzini, EM, Peck-Radosavljevic, M, Borghi, A, Ma, YT, Stoehr, F, Bettinger, D, Giuffrida, P, Aithal, GP, Lin, Y-M, Spreafico, C, Giampalma, E, Johnson, P & Cucchetti, A 2023, '', Cardiovascular and Interventional Radiology, vol. 46, no. 4, pp. 449-459.

BILCAP study group 2022, '', Journal of Clinical Oncology , vol. 40, no. 18, pp. 2048-2057.

L枚ffler, MW, Gori, S, Izzo, F, Mayer-Mokler, A, Ascierto, PA, K枚nigsrainer, A, Ma, YT, Sangro, B, Francque, S, Vonghia, L, Inno, A, Avallone, A, Ludwig, J, Alcoba, DD, Flohr, C, Aslan, K, Mendrzyk, R, Schuster, H, Borrelli, M, Valmori, D, Chaumette, T, Heidenreich, R, Gouttefangeas, C, Forlani, G, Tagliamonte, M, Fusco, C, Penta, R, I帽arrairaegui, M, Gnad-Vogt, U, Reinhardt, C, Weinschenk, T, Accolla, RS, Singh-Jasuja, H, Rammensee, H-G & Buonaguro, L 2022, '', Clinical Cancer Research, vol. 28, no. 12, pp. 2555-2566.

Razak, RA, Fletcher, P, Kunene, V & Ma, YT 2021, '', Journal of Clinical Gastroenterology, vol. 55, no. 2, pp. 169-173.

Childs, A, Zakeri, N, Ma, YT, O鈥橰ourke, J, Ross, P, Hashem, E, Hubner, RA, Hockenhull, K, Iwuji, C, Khan, S, Palmer, DH, Connor, J, Swinson, D, Darby, S, Braconi, C, Roques, T, Yu, D, Luong, TV & Meyer, T 2021, '', British Journal of Cancer, vol. 125, no. 10, pp. 1350-1355.

Lamarca, A, Palmer, DH, Wasan, HS, Ross, PJ, Ma, YT, Arora, A, Falk, S, Gillmore, R, Wadsley, J, Patel, K, Anthoney, A, Maraveyas, A, Iveson, T, Waters, JS, Hobbs, C, Barber, S, Ryder, WD, Ramage, J, Davies, LM, Bridgewater, JA & Valle, JW 2021, '', The Lancet Oncology, vol. 22, no. 5, pp. 690-701.

Virtakoivu, R, Rannikko, JH, Viitala, M, Vaura, F, Takeda, A, L枚nnberg, T, Koivunen, J, Jaakkola, P, Pasanen, A, Shetty, S, Jonge, MJAD, Robbrecht, D, Ma, YT, Skytt盲, T, Minchom, A, Jalkanen, S, Karvonen, MK, Mandelin, J, Bono, P & Hollmen, M 2021, '', Clinical Cancer Research, vol. 27, no. 15, pp. 4205-4220.

Sagar, VM, Herring, K, Curbishley, S, Hodson, J, Fletcher, P, Karkhanis, S, Mehrzad, H, Punia, P, Shah, T, Shetty, S & Ma, YT 2021, '', OncoTarget, vol. 12, no. 24, pp. 2338-2350.

Johnson, PJ, Dhanaraj, S, Berhane, S, Bonnett, L & Ma, YT 2021, '', British Journal of Cancer, vol. 125, no. 5, pp. 714-716.

Hashimoto, A, Sarker, D, Reebye, V, Jarvis, S, Sodergren, MH, Kossenkov, A, Sanseviero, E, Raulf, N, Vasara, J, Andrikakou, P, Meyer, T, Huang, K-W, Plummer, R, Chee, CE, Spalding, D, Pai, M, Khan, S, Pinato, DJ, Sharma, R, Basu, B, Palmer, D, Ma, Y-T, Evans, J, Habib, R, Martirosyan, A, Elasri, N, Reynaud, A, Rossi, JJ, Cobbold, M, Habib, NA & Gabrilovich, DI 2021, '', Clinical Cancer Research, vol. 27, no. 21, pp. 5961-5978.

Ma, YT 2020, '', Clinical Cancer Research.

Kalisvaart, M, Broadhurst, D, Marcon, F, Pande, R, Schlegel, A, Sutcliffe, R, Marudanayagam, R, Mirza, D, Chatzizacharias, N, Abradelo, M, Muiesan, P, Isaac, J, Ma, YT, Mcconville, C & Roberts, K 2020, '', HPB : the official journal of the International Hepato Pancreato Biliary Association, vol. 22, no. 9, pp. 1240-1249.

Review article

Lawson, A, Kamarajah, SK, Parente, A, Pufal, K, Sundareyan, R, Pawlik, TM, Ma, YT, Shah, T, Kharkhanis, S, Dasari, BVM & Sahin, I (ed.) 2023, '', Cancers, vol. 15, no. 12, 3166.